GYRE
GYRE THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$6.30
+3.37%Price chart
Sep 21Sep 24Sep 29Oct 2Oct 7Oct 12Oct 15Oct 20
Key dataOct 20, 2026
Open$6.14
From 52W high−28.14%
Volume42983.00
Market cap$667.48M
P/E (TTM)—
P/S (TTM)5.6x
Div yield—
Key dataOct 20, 2026
Open
$6.14
From 52W high
−28.14%
Volume
42983.00
Market cap
$667.48M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−51.8x
P/E (TTM)
—
RSI (14)
38.1
MomentumView details →
1D Return
+3.37%
YTD Return
−11.34%
SummaryUpdated Jun 1, 2026
Gyre Therapeutics, Inc. (NASDAQ:GYRE) is a pharmaceutical company founded in 2002 and headquartered in San Diego, California. The company went public in 2006 and operates as a subsidiary of GNI USA, Inc. Gyre specializes in developing and commercializing small-molecule drugs that target organ fibrosis, a medical condition where healthy tissue is replaced by scar tissue, leading to organ dysfunction. The company has successfully brought its lead drug to market and maintains an active pipeline of treatments for various fibrotic diseases affecting the lungs, liver, and other organs.
Similar companies
Latest newsMore news →